FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer.

David R Spigel,Jamie E Chaft,Scott Gettinger,Bo H Chao,Luc Dirix,Peter Schmid,Laura Q M Chow,Rodney J Hicks,Larry Leon,Jill Fredrickson,Marcin Kowanetz,Alan Sandler,Roel Funke,Naiyer A Rizvi

Journal of Thoracic Oncology（2018）

引用 116|浏览6

暂无评分

摘要

Atezolizumab monotherapy showed clinical activity in patients with NSCLC, including those with brain metastases; safety was consistent with previous trials. Atezolizumab has completed phase III monotherapy studies in second-line; front-line trials are ongoing, confirming these favorable results.

查看译文

关键词

NSCLC,Immunotherapy,Anti–PD-L1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要